These effects were present in the KRAS codon 12/13 wild-type population ( HR OS : 0.42 ; HR PFS : 0.54 ) , while no impact of primary tumor location was evident in patients with KRAS codon 12/13 mutant tumors ( HR OS : 1.3 ; HR PFS : 1.01 ) .